Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review

The stock market tumbled this week on the less-dovish Fed rate-cut outlook, with Treasury yields hitting five-month highs.

Investors Business Daily

Novo Nordisk faces stock market bloodbath after drug trial disappoints

Shares in Novo Nordisk plunged 20% on Friday.

Fortune

Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Ozempic May Face Investigation Over Vision-Threatening Condition In Some Patients

Danish health authorities asked the European Union to review two studies linking Novo Nordisk's diabetes drug, Ozempic, to a rare eye condition.

International Business Times

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

MarketBeat

The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market

An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs.

Investors Business Daily

Is Zepbound or Wegovy better for weight loss? New clinical trial reveals which medication sheds more pounds

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says

In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo Nordisk’s Wegovy shed more than 33 pounds

The Independent UK

Battle Of The Weight-Loss Behemoths: Eli Lilly Whomps Novo Nordisk

Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head-to-head study.

Investors Business Daily

Eli Lilly stock higher following surprise weight loss treatment data

Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.

The Street

Five things you should know about the HIV epidemic

It is 40 years since Aids was first identified. Major strides have been made since the spread of the virus reached epidemic proportions in 1995 when 3.3 million people were infected with HIV and just under one million people died.

The Conversation

What the Options Market Tells Us About Novo Nordisk

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 14 unusual trades.

Benzinga

Stock Market Today: The S&P 500 Reclaims the 6K Level

Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.

Kiplinger

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs

The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ to Denmark’s economy

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion people living with obesity.

Investors Business Daily

RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?

Robert F. Kennedy Jr.'s potential appointment to HHS has spooked Eli Lilly stock and stocks tied to popular weight-loss drugs.

Salon

Wegovy on sale in China, cheaper than US

The medication is currently available in 16 other countries

International Business Times

Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Buy This Pharma Stock to Bet on the Next Blockbuster Weight-Loss Drug

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its…

The Independent UK

Drugmakers see stocks tank after RFK Jr is nominated to oversee health department

JP Morgan Chase analysts say they’re ‘not surprised’ sector has come ‘under pressure’ since Kennedy’s nomination

Investors Business Daily

Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review

The stock market surged to highs on Donald Trump's election win. A Fed rate cut and a slew of big earnings reports filled out a busy week.

The Street

New health care policy changes will soon affect weight-loss drugs

The weight-loss industry may become more accessible to the average American.

Investors Business Daily

Novo Nordisk Slumps On Tightened Outlook As Wegovy Beats, But Ozempic Lags

Novo Nordisk stock fell Wednesday after the drugmaker's weight-loss drug beat forecasts, but Ozempic sales missed.

International Business Times

Obesity Drug Maker Novo Nordisk Posts Strong Profit

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.

Fortune

Danish town where Ozempic is made has highest rates of overweight children in Denmark

Novo Nordisk faces a challenge turning around the fortunes of residents in a major Danish manufacturing hub.

1 2 3 4 5

People

Lars Fruergaard Jørgensen

11 stories

Alan Crawford

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.